A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

Table 1 Comparison between baseline and 6 or 12 months after ART initiation

Variable		Baseline to month 6 comparison ^a		Baseline to month 12 comparison ^a,b
	Baseline median (IQR)	Month 6 median (IQR)	P value	Month 12 median (IQR)	P value
Plasma HIV-1 RNA (copies/mL)	349,066 (149,106–919,173)	<100 (<100–154)	<0.001	<100 (<100–176)	<0.001
CD4 Cell count (cells/μL)	124 (79–164)	236 (159–323)	<0.001	240 (182–332)	<0.001
Angiopoietin-1 (ng/mL)	13.7 (10.2–19.1)	22.5 (16.1–30.2)	<0.001	15.8 (11.6–21.9)	0.006
Angiopoietin-2 (ng/mL)	1.50 (0.37–2.43)	0.86 (0.31–1.92)	0.012	0.70 (<0.03–1.59)	0.030
ANG-2/ANG-1 ratio	0.09 (0.02–0.18)	0.03 (0.01–0.08)	<0.001	0.03 (0.003–0.11)	0.002
Soluble ICAM-1 (ng/mL)	397.9 (338.0–489.7)	220.5 (185.2–292.5)	<0.001	255.2 (200.0–312.5)	<0.001
E-Selectin (ng/mL)	24.2 (16.6–32.3)	13.7 (7.4–20.0)	<0.001	25.2 (18.5–30.4)	0.29
VCAM-1 (ng/mL)	763.8 (524.3–1107.6)	762.5 (537.0–1,013.3)	0.63	497.8 (407.2–628.6)	<0.001

ART antiretroviral therapy, IQR interquartile range.
^a Although 90 women completed the study at month 12, there was insufficient sample from one woman for testing of endothelial markers at this time-point. Therefore, there were 95 paired samples for the baseline to month 6 comparison and 89 paired samples for the baseline to month 12 comparison for all variables presented above except plasma HIV-1 RNA (90 paired samples available).
^b Differences between angiopoietin-1, E-selectin, and VCAM-1 levels between month 6 and month 12 were all significant at p < 0.001.

ISSN: 1471-2334